The “black box” warning on the popular diabetes and weight loss drug semaglutide may be shifting from a cautionary black to a reassuring grey. A landmark study published in The Journal of Clinical Endocrinology & Metabolism reveals that semaglutide does not promote thyroid cancer; instead, it may suppress tumor growth by “reprogramming” the immune system to fight it.
Thyroid cancer is the most common endocrine malignancy, consisting primarily of papillary thyroid carcinoma (PTC) — which accounts for the vast majority of cases — and medullary thyroid cancer (MTC), a rarer form making up about 3% of diagnoses. Early rodent studies showed increased MTC incidence, leading the U.S.
Food and Drug Administration to mandate a black box warning for patients with a family history of the disease. However, human data remained mixed, leaving a gap between preclinical fears and clinical reality.
This latest study provides the mechanistic evidence needed to alleviate these concerns. Using mouse models implanted with PTC tumors and cell cultures, researchers found that semaglutide significantly reduced tumor size.
Crucially, the drug did not directly affect cancer cell proliferation.
Endocrine News published a clinical update in Research Highlights on 12 Feb 2026.
The item focuses on New Research Challenges Fears of Semaglutide-Linked Thyroid Cancer Risk.
Review the original article for the full source wording and details.